Targovax’s ONCOS-102 mesothelioma 12-month data powerfully demonstrate broad immune activation linked to clinical benefit
· Encouraging PFS and survival data in ONCOS-102-treated first line patients as 31 patients have now completed 12 months follow-up · Mechanistic evidence of profound immune activation in ONCOS-102-treated patients associated with better clinical outcomes · Immune activation data provides clear scientific rationale for anti-PD1/L1 checkpoint inhibitor combination in upcoming trial in first line mesothelioma Oslo, Norway, 22 June 2020 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today releases